PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial
PharmAla Biotech Holdings Inc. (OTC:MDXXF), a Canadian company specializing in MDMA research and development, announced its selection as a supplier for a clinical trial at the University of Texas, San Antonio. The trial will focus on testing a novel dosage form of PharmAla’s proprietary LaNeo MDMA.
This development follows a grant application by the research team, which will explore the potential of the new dosage form in an investigator-led human clinical trial. PharmAla will provide …